制度・支援
指定難病 — No.279

巨大静脈奇形(頚部口腔咽頭びまん性病変)

検索語 Venous Malformation ・ 最終更新 2026-09-17 11:11 ・ 最新に更新

Data Sheet
指定 No.279
Src PubMed · CT.gov · jRCT

これは医療アドバイスではありません。診断・治療の判断は必ず主治医にご相談ください。論文や治験は「今わかっている研究の状況」を示すもので、効果を保証するものではありません。

( 01 )EVIDENCE / PUBMED · 5件

世界の論文

直近の研究を、やさしい日本語で

各論文の見出しにある「確からしさ」は、その研究がどれくらい信頼できるかの目安です。「理論段階」はまだ仮説に近く、下にいくほど多くの患者で検証されていて、「メタ解析」がもっとも信頼できます。

システマティックレビュー/メタ解析
MK-01 · PMID 42750542

遺伝子変異が原因の血管の病気に対する、より精密な医療について

Precision Medicine for Somatic Mutation-Driven Vascular Anomalies

Abstract / 原文

Vascular anomalies, including proliferative vascular tumours and structural malformations, are largely driven by postzygotic somatic mutations that constitutively activate key signalling pathways, mainly the PI3K/AKT/mTOR and RAS/MAPK pathways. This molecular understanding has shifted clinical management from empiric interventions towards precision medicine. In this review, the interactions between somatic mosaicism, germline predispositions (e.g., PTEN hamartoma tumour syndrome), and microenvironmental risk factors in the context of lesional progression are described. We synthesized data on genotype‒phenotype correlations-such as PIK3CA mutations in lymphatic and venous malformations, KRAS/MAP2K1 mutations in arteriovenous malformations, and cerebral cavernous malformation (CCM) complex dysfunctions in cerebral cavernous anomalies-while fundamentally differentiating the mechanistic dependencies of true malformations from those of proliferative tumours. Targeted therapies, including mTOR, PI3Kα, and MEK inhibitors, have exhibited significant clinical efficacy in the treatment of pathway-specific anomalies. Despite these advances, therapeutic resistance and drug dependency persist. Future directions include the development of integrated diagnostic frameworks combining tissue biopsies with longitudinal cell-free DNA (cfDNA) monitoring, optimizing dual-pathway combination strategies, and advancing cellular models to reshape the management of vascular anomalies.

今の治療への意味この論文は、血管の病気の原因となっている遺伝子変異を特定し、それに応じた新しい治療法(標的薬)の効果についてまとめたものです。これらの治療法は、一部の患者さんで効果が期待されていますが、まだ研究段階のものも含まれます。

この論文で紹介されている治療法は、まだ新しいものが多く、すべての人に有効とは限りません。また、治療法によっては副作用や効果が出にくい場合もあります。治療については、必ず主治医にご相談ください。

Journal
The British journal of dermatology(2026 Sep)
Authors
4名
Type
Journal Article

複数の研究結果をまとめたレビュー論文です。

PubMedで原文を見る
非ランダム化試験
MK-02 · PMID 42749324

3Dプリンターで作られた人工関節を使った膝関節の手術の効果について

[Effectiveness of cementless total knee arthroplasty with three-dimensional-printed trabecular metal interface]

Abstract / 原文

OBJECTIVE: To investigate the short- and mid-term effectiveness and prosthesis survival rate in patients undergoing total knee arthroplasty (TKA) using domestic cementless knee prostheses with three-dimensional (3D)-printed trabecular metal interface. METHODS: A retrospective analysis was performed on the clinical data of 79 patients who underwent primary TKA for end-stage knee disorders, met the selection criteria and were treated between December 2021 and March 2022. There were 39 patients in the cementless group receiving cementless knee prostheses with 3D-printed trabecular metal interface, and 40 patients in the cemented group adopting posterior-stabilized cement-fixed knee prostheses. Baseline data including age, gender, body weight, disease type, disease duration, and preoperative Knee Society Score (KSS) (clinical score and function score) showed no significant differences between the two groups ( P>0.05). Operation time, intraoperative blood loss, and complications were recorded and compared between groups. KSS clinical and function scores before operation and at last follow-up were used to evaluate knee functional recovery. Radiographic assessment was conducted to detect prosthesis loosening, osteolysis, prosthesis subsidence, joint dislocation, and other abnormalities. Prosthesis survival rate was calculated with complete or partial prosthesis removal defined as the endpoint event, and Kaplan-Meier method was adopted to plot prosthesis survival curves. RESULTS: All patients successfully completed surgery. No significant intergroup differences were found in operation time and intraoperative blood loss ( P>0.05). All patients in the cementless group and cemented group were followed up for (28.4±2.4) months and (28.2±2.8) months respectively, without significant difference ( t=-0.274, P=0.785). At last follow-up, both KSS clinical and function scores were significantly higher than preoperative values in both groups ( P<0.05), while no significant intergroup differences were observed in the changes of each score ( P>0.05). X-ray films at last follow-up revealed no prosthesis loosening, osteolysis, prosthesis subsidence, or joint dislocation in any patient. During follow-up, 5 cases of intermuscular venous thrombosis occurred in the cementless group; in the cemented group, there were 6 cases of intermuscular venous thrombosis, 1 case of poor wound healing, 1 case of periprosthetic joint infection, 1 case of periprosthetic fracture, and 1 case of all-cause death. The complication rates of the two groups (12.8% vs 25.0%) were not different ( P>0.05). One revision surgery was performed for periprosthetic joint infection and 1 for periprosthetic fracture in the cemented group, corresponding to a prosthesis survival rate of 95.0%; no endpoint events occurred in the cementless group, with a prosthesis survival rate of 100.0%. Kaplan-Meier survival curve analysis demonstrated no significant difference in prosthesis survival rates between the two groups (Log-rank test: χ 2=2.028, P=0.154). CONCLUSION: TKA performed with domestic cementless knee prostheses featuring 3D-printed trabecular metal interface shows no obvious disadvantages compared with cemented prostheses in terms of postoperative function, complication rate, and prosthesis survival rate, which represents a safe and viable prosthesis option.

今の治療への意味この研究では、3Dプリンターで作られた新しいタイプの人工関節が、従来の人工関節と同程度の効果や安全性を持つ可能性が示唆されています。ただし、これは比較的新しい技術であり、長期的な効果についてはさらなる観察が必要です。

この研究は、限られた人数の患者さんを対象としたものです。新しい治療法や手術方法については、必ず主治医とよく相談し、ご自身の状態に合った選択をしてください。

Journal
Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery(2026 Sep)
Authors
5名
Type
English Abstract, Journal Article

過去の手術記録を振り返って、2つのグループを比較した研究です。

PubMedで原文を見る
症例報告
MK-03 · PMID 42748092

死産後、長期間お腹の中に留まった胎児の脳を取り出すための、硬膜を守る方法

Dura mater-preserving technique for fetal brain extraction after intrauterine death with prolonged retention

Abstract / 原文

Examination of the fetal brain represents a crucial step in the diagnostic assessment of fetal death in utero, particularly in cases of unexplained intrauterine fetal death (IUFD). Prolonged intrauterine retention, advanced autolysis, and the intrinsic structural immaturity of the fetal brain frequently compromise tissue integrity, limiting diagnostic evaluability. We describe a brain extraction technique preserving the dura mater combined with a modified alcohol-formalin-acetic acid fixation protocol aimed at improving morphological preservation and diagnostic yield. Between 2017 and 2019, 295 fetal autopsies were performed at the regional reference center for SIUD-IRCCS Istituto Giannina Gaslini, Genoa, Italy. The method enables en bloc removal of the brain completely enveloped by the intact dura mater, which acts as a protective scaffold during handling and fixation. The brain is suspended in a modified Culling solution (40% buffered formalin at 10%, 40% ethanol at 95%, 20% glacial acetic acid) for approximately 20 days prior to serial sectioning according to the Charcot's technique. This approach appears to reduce mechanical disruption even in severely macerated cases, ensures uniform tissue compaction, shortens fixation times compared with formalin alone, and preserves cortical, ventricular, and brainstem anatomical relationships. It also allows gross exclusion of major abnormalities, including extensive intraventricular and intraparenchymal hemorrhages, and enables systematic inspection and sampling of the dural venous sinuses. Histological and immunohistochemical analyses demonstrated satisfactory preservation quality comparable to conventional methods. This simple and reproducible technique enhances evaluability in fetal autopsies and supports more reliable etiological assessment in cases of IUFD.

今の治療への意味この論文は、死産後の胎児の脳をより正確に調べるための新しい技術を紹介しています。この技術は、脳の構造をより良く保存し、死因の特定に役立つ可能性があります。

この論文は、胎児の死後の検査に関する技術的な内容です。直接的な治療法ではありません。ご自身の状況と照らし合わせて、主治医にご相談ください。

Journal
Journal of forensic sciences(2026 Sep)
Authors
7名
Type
Journal Article

新しい技術や方法を提案する論文です。

PubMedで原文を見る
症例報告
MK-04 · PMID 42746649

ゴルド症候群の子供が、胃腸からの出血を起こした珍しいケース

A Rare Case of Gould Syndrome Presenting With Gastrointestinal Bleeding in a Pediatric Patient

Abstract / 原文

Gould syndrome, caused by COL4A1/COL4A2 mutations, is a rare multisystem disorder characterized by basement membrane defects leading to vascular fragility, cerebral small vessel disease, seizures, and renal involvement. While vascular complications are well-described, gastrointestinal bleeding remains exceedingly rare. We describe a four-year-old female with a known diagnosis of Gould syndrome who presented with hemodynamically significant hematochezia. Colonoscopy demonstrated tortuous submucosal vascular lesions consistent with colonic varices in the sigmoid colon, which were treated with bipolar probe electrocautery; an additional non-bleeding varix was noted at the hepatic flexure. Computed tomography (CT) angiography and time-resolved imaging of contrast kinetics magnetic resonance imaging (TRICKS MRI) revealed abnormal venous structures in the mesentery and bowel without evidence of arteriovenous malformation or portal-systemic shunting, congruent with endoscopic findings. There was no clinical or radiographic evidence of portal hypertension. This case expands the phenotypic spectrum of Gould syndrome by providing detailed evidence of gastrointestinal venous abnormalities and highlights gastrointestinal bleeding as a potential underrecognized manifestation of COL4A1/2-related disease.

今の治療への意味この論文は、ゴルド症候群というまれな病気で、胃腸からの出血が起こる可能性があることを示唆しています。もしお子さんがこの病気で、胃腸の不調がある場合は、主治医に相談することが重要です。

これは非常にまれな病気の、一つのケースについての報告です。すべての人に当てはまるわけではありません。お子さんの症状については、必ず主治医にご相談ください。

Journal
Cureus(2026 Aug)
Authors
3名
Type
Case Reports, Journal Article

非常にまれな病気の、一つの具体的なケースについて報告したものです。

PubMedで原文を見る
症例報告
MK-05 · PMID 42744778

左胃大網静脈と腎静脈が直接つながる、生まれつきの血管の異常について

Direct left gastroepiploic-renal vein communication: a novel variant of congenital extrahepatic portosystemic shunt

Abstract / 原文

Congenital portosystemic shunts are rare developmental anomalies that permit portal blood to bypass hepatic filtration. We describe a novel gastrorenal shunt identified during routine cadaveric dissection. A large aberrant vein connecting the left renal vein directly to the left gastroepiploic vein, forming an unusual connection between the systemic and portal circulations. The portal venous system was otherwise intact, with no evidence of hepatic fibrosis or portal hypertension. This configuration does not conform to previously reported portosystemic shunt malformation patterns and is most consistent with a previously unreported variant of a Type II congenital extrahepatic portosystemic shunt.

今の治療への意味この論文は、生まれつきの血管の異常の新しいタイプを発見したという報告です。この発見が、将来的に同様の血管異常を持つ患者さんの診断や治療に役立つ可能性があります。

これは非常にまれな解剖学的な発見に関する報告であり、直接的な治療法ではありません。ご自身の健康状態については、必ず主治医にご相談ください。

Journal
Anatomy & cell biology(2026 Sep)
Authors
3名
Type
Case Reports, Journal Article

解剖学的な発見に関する、一つの具体的なケースについての報告です。

PubMedで原文を見る
( 02 )TRIALS / JAPAN · 0件

日本で参加できる治験

現在 募集中のもの

日本で現在募集中の治験は見つかりませんでした。下の公式レジストリで条件を変えると見つかる場合があります。
( 03 )REGISTRY / jRCT

治験をもっと探す

日本の公式レジストリで全件を確認

上の一覧は ClinicalTrials.gov の一部です。日本国内の治験の多くは、日本の公式レジストリ jRCT にのみ登録されています。下記から最新の全件を確認できます。

jRCT で検索日本の臨床研究実施計画 公開システム「対象疾患名」に 巨大静脈奇形(頚部口腔咽頭びまん性病変) を入力し、「募集状況」で 募集中 にチェックして検索します。ClinicalTrials.gov で全件を見る世界最大の治験データベース(英語)「巨大静脈奇形(頚部口腔咽頭びまん性病変)・日本・募集中」の条件で一覧が開きます。

※ jRCTは自動の大量データ取得を禁じているため、本サービスは自動収集せず、ご自身が公式サイトで検索できるリンクでご案内しています(規約順守)。

お金・介護・制度巨大静脈奇形(頚部口腔咽頭びまん性病変)の療養に使えるかもしれない公的サポートを調べる医療費・生活費・介護の支援制度と相談先を、あなたの状況に合わせてご案内(回答は端末内で完結)
( 04 )SUPPORT

患者会・相談窓口

一人で抱え込まないでください

同じ病気の患者・家族とつながる、制度や生活の相談をする、といったときの窓口です。

全国の相談先

※ お住まいの都道府県の「難病相談支援センター」でも、医療費助成や療養生活の相談ができます(難病情報センターから探せます)。